BCLI Investors Have Opportunity to Lead Brainstorm Cell Therapeutics Inc. Securities Fraud Lawsuit
BENSALEM, Pa., Nov. 21, 2023 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Brainstorm Cell Therapeutics Inc. ("Brainstorm Cell" or the "Company") (NASDAQ: BCLI).
Class Period: August 15, 2022 – September 27, 2023
Lead Plaintiff Deadline:January 2, 2024
Investors suffering losses on their Brainstorm Cell investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.
The complaint filed alleges that, throughout the Class Period, Defendants failed to disclose to investors that: (1) Brainstorm Cell downplayed the severity of the FDA's refusal to file letter; (2) Brainstorm Cell continued to conceal the risks associated with the submission of the BLA; and (3) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contacts
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com
View original content:https://www.prnewswire.com/news-releases/bcli-investors-have-opportunity-to-lead-brainstorm-cell-therapeutics-inc-securities-fraud-lawsuit-301995198.html
SOURCE Law Offices of Howard G. Smith
Ausgewählte Hebelprodukte auf Brainstorm Cell Therapeutics
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Brainstorm Cell Therapeutics
Der Hebel muss zwischen 2 und 20 liegen
Aktuelle Brainstorm Cell Therapeutics Aktie News
Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.
Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv
Brainstorm Cell Therapeutics Analysen
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Brainstorm Cell Therapeutics nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen
| Datum | Rating | Analyst | |
|---|---|---|---|
| 19.12.16 | Brainstorm Cell Therapeutics Buy | Maxim Group | |
| 22.12.15 | Brainstorm Cell Therapeutics Buy | Maxim Group |